Effect of probiotics on giardiasis. Where are we?

Detalhes bibliográficos
Autor(a) principal: Ventura, Luciana Laranjo Amorim
Data de Publicação: 2018
Outros Autores: Oliveira, Dirce Ribeiro de, Gomes, Maria Aparecida, Torres, Marcia Regina Fantoni
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Pharmaceutical Sciences
Texto Completo: https://www.revistas.usp.br/bjps/article/view/153811
Resumo: Giardiasis, an intestinal infection caused by Giardia lamblia, was recently included in the ‘Neglected Diseases Initiative’ by the World Health Organization. Symptomatic patients can develop mild diarrhea up to a severe malabsorption syndrome, and children may show significantly impaired cognitive and physical development. Currently, nitroimidazoles are the main class of antibiotic used to treat giardiasis. Despite the efficacy of these drugs, adverse effects and reported resistance have increased, encouraging studies to identify and develop therapeutic alternatives. In this context, probiotics may represent an attractive option. Probiotics are defined as live microorganisms that, when administered in suitable amounts, confer a health benefit to the host. The use of probiotics in the treatment of parasitosis has been suggested because of its beneficial effects, such as a reduced time of gastrointestinal symptoms and parasite load in animal models and humans. Probiotics have been studied as an alternative treatment for giardiasis. In this review, we evaluated probiotic effectiveness in the treatment and prevention of this disease. Based on the studies examined herein, we conclude that probiotics have a beneficial effect on the modulation of giardiasis.
id USP-31_1437a60cd50e41ce3227244dd2c080bf
oai_identifier_str oai:revistas.usp.br:article/153811
network_acronym_str USP-31
network_name_str Brazilian Journal of Pharmaceutical Sciences
repository_id_str
spelling Effect of probiotics on giardiasis. Where are we?Giardia lambliaGiardiasisProbiotics/effects/evaluationGiardiasis, an intestinal infection caused by Giardia lamblia, was recently included in the ‘Neglected Diseases Initiative’ by the World Health Organization. Symptomatic patients can develop mild diarrhea up to a severe malabsorption syndrome, and children may show significantly impaired cognitive and physical development. Currently, nitroimidazoles are the main class of antibiotic used to treat giardiasis. Despite the efficacy of these drugs, adverse effects and reported resistance have increased, encouraging studies to identify and develop therapeutic alternatives. In this context, probiotics may represent an attractive option. Probiotics are defined as live microorganisms that, when administered in suitable amounts, confer a health benefit to the host. The use of probiotics in the treatment of parasitosis has been suggested because of its beneficial effects, such as a reduced time of gastrointestinal symptoms and parasite load in animal models and humans. Probiotics have been studied as an alternative treatment for giardiasis. In this review, we evaluated probiotic effectiveness in the treatment and prevention of this disease. Based on the studies examined herein, we conclude that probiotics have a beneficial effect on the modulation of giardiasis.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2018-07-26info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/15381110.1590/s2175-97902018000217360Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 2 (2018); e17360Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 2 (2018); e17360Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 2 (2018); e173602175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/153811/150191Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)info:eu-repo/semantics/openAccessVentura, Luciana Laranjo AmorimOliveira, Dirce Ribeiro deGomes, Maria AparecidaTorres, Marcia Regina Fantoni2019-03-17T14:04:07Zoai:revistas.usp.br:article/153811Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2019-03-17T14:04:07Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Effect of probiotics on giardiasis. Where are we?
title Effect of probiotics on giardiasis. Where are we?
spellingShingle Effect of probiotics on giardiasis. Where are we?
Ventura, Luciana Laranjo Amorim
Giardia lamblia
Giardiasis
Probiotics/effects/evaluation
title_short Effect of probiotics on giardiasis. Where are we?
title_full Effect of probiotics on giardiasis. Where are we?
title_fullStr Effect of probiotics on giardiasis. Where are we?
title_full_unstemmed Effect of probiotics on giardiasis. Where are we?
title_sort Effect of probiotics on giardiasis. Where are we?
author Ventura, Luciana Laranjo Amorim
author_facet Ventura, Luciana Laranjo Amorim
Oliveira, Dirce Ribeiro de
Gomes, Maria Aparecida
Torres, Marcia Regina Fantoni
author_role author
author2 Oliveira, Dirce Ribeiro de
Gomes, Maria Aparecida
Torres, Marcia Regina Fantoni
author2_role author
author
author
dc.contributor.author.fl_str_mv Ventura, Luciana Laranjo Amorim
Oliveira, Dirce Ribeiro de
Gomes, Maria Aparecida
Torres, Marcia Regina Fantoni
dc.subject.por.fl_str_mv Giardia lamblia
Giardiasis
Probiotics/effects/evaluation
topic Giardia lamblia
Giardiasis
Probiotics/effects/evaluation
description Giardiasis, an intestinal infection caused by Giardia lamblia, was recently included in the ‘Neglected Diseases Initiative’ by the World Health Organization. Symptomatic patients can develop mild diarrhea up to a severe malabsorption syndrome, and children may show significantly impaired cognitive and physical development. Currently, nitroimidazoles are the main class of antibiotic used to treat giardiasis. Despite the efficacy of these drugs, adverse effects and reported resistance have increased, encouraging studies to identify and develop therapeutic alternatives. In this context, probiotics may represent an attractive option. Probiotics are defined as live microorganisms that, when administered in suitable amounts, confer a health benefit to the host. The use of probiotics in the treatment of parasitosis has been suggested because of its beneficial effects, such as a reduced time of gastrointestinal symptoms and parasite load in animal models and humans. Probiotics have been studied as an alternative treatment for giardiasis. In this review, we evaluated probiotic effectiveness in the treatment and prevention of this disease. Based on the studies examined herein, we conclude that probiotics have a beneficial effect on the modulation of giardiasis.
publishDate 2018
dc.date.none.fl_str_mv 2018-07-26
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/bjps/article/view/153811
10.1590/s2175-97902018000217360
url https://www.revistas.usp.br/bjps/article/view/153811
identifier_str_mv 10.1590/s2175-97902018000217360
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/bjps/article/view/153811/150191
dc.rights.driver.fl_str_mv Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
dc.source.none.fl_str_mv Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 2 (2018); e17360
Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 2 (2018); e17360
Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 2 (2018); e17360
2175-9790
1984-8250
reponame:Brazilian Journal of Pharmaceutical Sciences
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Brazilian Journal of Pharmaceutical Sciences
collection Brazilian Journal of Pharmaceutical Sciences
repository.name.fl_str_mv Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)
repository.mail.fl_str_mv bjps@usp.br||elizabeth.igne@gmail.com
_version_ 1800222913746436096